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Structural Basis of Multidrug Recognition
by BmrR, a Transcription Activator
of a Multidrug Transporter
1998). For one such regulator, the Bacillus subtilis pro-
tein BmrR (Ahmed et al., 1994), which controls the tran-
scription of the multidrug transporter gene bmr (Neyfakh
et al., 1991), the binding of diverse inducers has been
demonstrated directly. Structurally dissimilar substrates
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²Center for Pharmaceutical Biotechnology of the Bmr transporter, such as tetraphenylphospho-
nium (TPP) and rhodamine (Ahmed et al., 1994), as wellUniversity of Illinois at Chicago
Chicago, Illinois 60607 as a number of other aromatic cationic compounds
(Markham et al., 1997), have been shown to bind to
BmrR and stimulate transcription from the bmr pro-
moter. Unlike multidrug transporters, the cytosolic BmrR
Summary is amenable to structural studies and thus provides a
promising model system for understanding the struc-
Multidrug-efflux transporters demonstrate an unusual tural principles of multidrug recognition.
ability to recognize multiple structurally dissimilar tox- BmrR belongs to the MerR family of transcription reg-
ins. A comparable ability to bind diverse hydrophobic ulators (Sadowsky et al., 1991; Summers, 1992; Holmes
cationic drugs is characteristic of the Bacillus subtilis et al., 1993; Ansari et al., 1995; Utschig et al., 1995;
transcription regulator BmrR, which upon drug binding Gaudu and Weiss, 1996; Hidalgo et al., 1997). This pro-
activates expression of the multidrug transporter Bmr. tein is composed of an amino-terminal helix-turn-helix
Crystal structures of the multidrug-binding domain of DNA-binding domain (residues 1±90) homologous to
BmrR (2.7 AÊ resolution) and of its complex with the the DNA-binding domains of other MerR-type proteins
drug tetraphenylphosphonium (2.8 AÊ resolution) re- (Ahmed et al., 1994), a linker region (residues 91±120),
vealed a drug-induced unfolding and relocation of and a carboxy-terminal domain (residues 121±279). The
an a helix, which exposes an internal drug-binding latter domain, named BRC (BmrR C terminus), has no
pocket. Tetraphenylphosphonium binding is mediated sequence homology to other proteins of the MerR family
by stacking and van der Waals contacts with multiple or any other protein in current databases. Purified BRC
hydrophobic residues of the pocket and by an electro- forms dimers and binds the aromatic cationic ligands
static interaction between the positively charged drug rhodamine and TPP with the same affinity as the full-
and a buried glutamate residue, which is the key to length BmrR: KD,Rho 5 1.5 mM and KD,TPP 5 100 mM (Mark-cation selectivity. Similar binding principles may be ham et al., 1996). To elucidate the structural and ste-
used by other multidrug-binding proteins. reochemical mechanisms of multidrug recognition by
BmrR, we undertook crystallographic studies on its car-
Introduction boxy-terminal drug-binding/dimerization domain. Here,
we report the structures of drug-free BRC to 2.7 AÊ reso-
One of the major mechanisms underlying multidrug re- lution and TPP-bound BRC to 2.8 AÊ resolution.
sistance in both prokaryotes (Nikaido, 1994; Paulsen
et al., 1996) and eukaryotes (Gottesman and Pastan, Results and Discussion
1993; Goffeau et al., 1997; Sharom, 1997) is the active
extrusion of numerous structurally unrelated cytotoxic Apo BRC Structure Determination
compounds by membrane proteins known as multidrug- The structure of the apo BRC was solved by multiple
efflux transporters. The broad substrate specificity dis- isomorphous replacement (Blundell and Johnson, 1976;
played by these transporters contrasts dramatically with Drenth, 1994). The R factor for the final model is 20.2%
the narrow chemical specificity of the vast majority of (Table 1). It includes 143 residues, 30 water molecules,
ligand-binding proteins. Despite extensive biochemical and one Mn21 ion. Residues 42±47, 77±80, and 142±147
studies, the structural mechanisms that multidrug trans- are disordered and not included in the final model (al-
porters use to recognize dissimilar compounds remain though BRC constitutes residues 121±279 of BmrR, in
obscure, primarily because of the dearth of structural this paper we refer to them, for convenience, as residues
information on any of these membrane proteins. 1±159). The stereochemical quality of the model is excel-
The phenomenon of multidrug recognition is not con- lent with no Ramachandran outliers, as assessed by the
fined to multidrug transporters. In bacteria, several tran- program PROCHECK (Laskowski et al., 1993).
scription regulators of these transporters have been
demonstrated to promote transporter expression in re-
Overall Structure of the Apo BRC
sponse to structurally dissimilar toxic compounds (Lo-
The BRC monomer is composed of eight b strands and
movskaya et al., 1995; Ma et al., 1996; Grkovic et al.,
three a helices (Figure 1A). The core of the protein is
created primarily by the b strands, which form an anti-
parallel b sheet with the topology b1-b6-b8-b7-b3-b4-³ To whom correspondence should be addressed (e-mail: brennanr@
b2-b5. BRC has a unique fold as determined by theohsu.edu).
three-dimensional homology-search algorithm Dali (Holm§ Present address: Influx Inc., Chicago Technology Park, Chicago,
Illinois 60612. and Sander, 1993), but its structure resembles the b
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Table 1. Crystallographic Data
Apo BRC SeMet KAuCl4 HgCl2 TPP Complex
Resolution (AÊ ) 24.0±2.7 10.0±3.0 10.0±3.0 10.0±3.0 42.2±2.8
Total observations 65,480 25,303 24,171 25,560 24,335
Unique reflections 8,264 5,692 5,887 3,036 5,322
Completeness (%) 100 96 100 51 95
Overall I/s(I) 10.3 10.2 11.0 11.1 14.7
Rsym (%)a 6.0 5.5 6.6 5.3 8.3
Highest resolution shellb
Completeness (%) 100 90
I/s(I) 1.6 3.8
Multiple Isomorphous ReplacementÐApo BRC
Riso (%)c 9.6 23.4 12.4
No. of sites 1 2 1
Rcullisd 0.49 0.69 0.57
Phasing powere 1.0 1.7 1.5
Overall figure of meritf 0.45 to 3 AÊ
Molecular ReplacementÐTPP Complex
Correlation coefficient (%) 65.1
Initial R factorg (%) 37.4
Refinement Apo BRC TPP Complex
Resolution range (AÊ ) 20.0±2.7 16.0±2.8
Reflections used in refinement 8,250 5,285
Completeness (%) 100 95
Amino acid residues 143 130
Protein atoms 1,171 1,045
Solvent molecules 30 11
Sulfate molecules 1
Mn21 atoms 1 1
R factorg (%) 20.2 23.5
Rfree (%) 27.4 32.6
Rms Deviations
Bond length (AÊ ) 0.011 0.014
Bond angles (8) 1.29 1.72
B factor (AÊ 2) 4.70 4.03
PROCHECK: Residues in Ramachandran Regions (%, No. of Residues)
Most favorable 82.9 (102) 74.5 (82)
Allowed 14.6 (18) 20.9 (23)
Generously allowed 2.4 (3) 2.7 (3)
Disallowed 0.0 (0) 1.8 (2)
a Rsym 5 S|Io2,I.|/Io, where Io is observed intensity, and ,I. is average intensity obtained from multiple observations of symmetry related
reflections.
b The highest resolution shell was 2.7±2.8 AÊ for the apo BRC structure and 2.8±2.9 AÊ for the BRC±TPP complex.
c Riso 5 S||FPH|2|FP||/S||FP|1|FPH||, where |FP| is the protein structure factor amplitude, and |FPH| is the heavy atom derivative structure factor
amplitude.
d Rcullis 5 S||FPH 6 FP|2FH(calc)|/S|FPH 6 FP|.
e Phasing power is [S|FPH(calc)|2/S{|FPH(obs)|2|FPH(calc)|}2]1/2.
f Figure of merit is ,|S P(a) eia/S P(a)|., where a is the phase and P(a) is the phase probability distribution.
g R factor 5 S||Fobs|2|Fcalc||/S|Fobs|.
barrel motif taken by members of the lipocalin family residues Lys-144 and Lys-145. However, in the crystal
structure, b8 strand is integrated into the core b sheet(Sacchettini and Gordon, 1993; LaLonde et al., 1994;
Flower, 1996). One side of the b sheet core is covered and remains associated with the protein.
by a 17-residue a helix, a3 (residues 107±123); a well-
defined 12-residue loop (residues 57±68); a 2-turn a he-
lix, a1 (residues 25±30); and a 3-turn a helix, a2 (residues Structure of the Dimer
There is one monomer in the asymmetric unit of the34±42), which are connected by a short turn. Surpris-
ingly, the crystal structure revealed the proteolytic crystal. However, biochemical data obtained from dy-
namic light scattering and gel filtration experiments indi-cleavage of the C-terminal b8 strand (residues 148±158)
from the preceding b7 strand that occurs during the cate that BRC is dimeric (Markham et al., 1996; Zhelez-
nova et al., 1997). Moreover, the full-length BmrR bindstrypsin digestion step in the course of protein purifica-
tion. Protein sequencing and electrospray mass spec- its operator as a dimer (Ahmed et al., 1994). To identify
the biologically relevant dimer, we considered the threetrometry confirmed that trypsin cleaves BRC between
Structural Basis of Multidrug Recognition by BmrR
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Figure 1. Ribbon Diagrams of the Mono-
meric and Dimeric Apo BRC
(A) Ribbon diagram of the BRC monomer with
the secondary structure elements depicted
as coils for a helices, arrows for b strands,
and tubes for other structures. Labeled are
the amino (N) and the carboxyl (C) termini
and the trypsin cleavage site. The protein is
composed of strand b1 (residues 6±10),
strand b2 (residues 13±18), helix a1 (residues
24±30), helix a2 (residues 34±42), strand b3
(residues 51±55), strand b4 (residues 69±74),
strand b5 (residues 89±93), strand b6 (resi-
dues 96±104), helix a3 (residues 107±123),
strand b7 (residues 132±137), and strand b8
(residues 149±157). The disordered residues
142±147 are not shown. Loops that have poor
electron density (residues 43±47 and 77±80)
are shown in white. Helix a2 (residues 34±42),
which becomes disordered upon TPP bind-
ing, is shown in red. This figure was generated
with MOLSCRIPT (Kraulis, 1991).
(B) Ribbon diagram of the BRC dimer. La-
beled are the amino (N) and the carboxyl (C)
termini and the drug-binding site residues
Glu-134 and Glu-1349. Shown in black as ball-
and-stick representations are the drug-bind-
ing site residue Glu-134, the metal-chelating
residues Glu-19 and His-70, and their two-
fold symmetry mates. The metal ion coordi-
nated at the dimer interface is shown as a
yellow sphere. The metal ion has been refined
as Mn21 at occupancy 0.5 with a resulting
thermal B factor of 18 AÊ 2. This figure was
generated with MOLSCRIPT (Kraulis, 1991).
potential dimers that are created by the symmetry oper- insoluble, whereas the Glu19Gln mutant, in which the
metal binding should be weaker, retains solubility but,ators of the tetragonal unit cell. In one of them, both
subunits are related by a crystallographic two-fold sym- unlike the wild-type variant, precipitates upon storage.
metry (Figure 1B). Furthermore, the buried surface area
of this dimer is z900 AÊ 2 per monomer (Honig and Internal Binding Site
The apo BRC structure reveals no pocket or cavity thatNicholls, 1995), whereas each of the two alternative di-
mers buries only z400 AÊ 2, which strongly indicates that would appear to serve as an obvious drug-binding site.
However, examination of the hydrophobic core of thethe symmetrical dimer corresponds to the biologically
relevant one. Nearly 65% of the buried dimer interface protein revealed an anomaly, a completely buried acidic
residue, Glu-134. The burial of a charged residue inis hydrophilic, and eight ionic and hydrogen-bonding
interactions stabilize the dimer. These involve OE1 of the protein core is normally considered energetically
unfavorable, yet in this structure, the carboxylate groupGlu-12 and NH1 of Arg-156; OE2 of Glu-12 and NH2 of
Arg-156; NE2 of Gln-58 and the carbonyl oxygen of Ile- of the glutamate is ªneutralizedº by hydrogen bonds to
the hydroxyl groups of Tyr-33 from the N cap of helix84; NE1 of Arg-69 and the carbonyl oxygen of Met-88;
and their symmetry-related mates. a2, Tyr-68 from the loop connecting strands b3 and b4,
and Tyr-110 from helix a3 (Figure 2). Such an arrange-The most unexpected feature of the dimer interface
is the presence of a subunit-tethering divalent metal ion ment, a negatively charged side chain surrounded by
aromatic moieties, would make an attractive binding siteresiding on a crystallographic two-fold axis. The metal
is tetrahedrally coordinated by the side chains of Glu- for aromatic/hydrophobic cationic drugs. Consequently,
the putative role of Glu-134 in drug binding was exam-19 (Me21-OE2, 1.8 AÊ ) and His-70 (Me21-NE2, 1.9 AÊ ) and
their two-fold symmetry mates, Glu199 and His709 (Fig- ined by substituting this residue with glutamine, alanine,
or lysine and by assaying rhodamine binding to eachure 1B). This metal ion has been refined as a Mn21 be-
cause of the presence of 2 mM MnCl2 in the crystalliza- mutant (Markham et al., 1996). The stability and solution
properties of all three mutant proteins were indistin-tion solution, but the relevant in vivo ion is unknown.
The importance of the divalent metal ion in dimer stabil- guishable from those of the wild-type BRC, indicating
that the mutant proteins were folded like the wild-typeity was indicated by two site-directed mutants His70Ala
and Glu19Gln. The His70Ala mutant, which lacks two protein. In addition, the Glu134Gln mutant crystallized
under the same conditions and in the same space groupof the four metal-coordinating residues, is completely
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Figure 2. An Fo-Fc Omit Map of Apo BRC Res-
idues Glu-134, Tyr-33, Tyr-68, and Tyr-110
Contoured at 3.5 s
Dashed lines indicate hydrogen bonds be-
tween the carboxylate moiety of Glu-134 and
hydroxyl groups of residues Tyr-33, Tyr-68,
and Tyr-110 with their distances given in AÊ .
This figure was generated with O (Jones et
al., 1991).
as the wild-type BRC. None of the mutants, however, However, when the flexible-loop residues 76 and 81±83,
which neighbor disordered residues 77±80, are ex-was able to bind rhodamine to any measurable extent
(at least 20-fold reduction as compared to wild type), cluded from the overlay, the rmsd is only 0.61 AÊ for the
monomer and 0.63 AÊ for the dimer. As found in thestrongly supporting the key electrostatic role of residue
Glu-134 in drug binding. It remained unclear, however, dimer interface of the apo protein, a divalent metal ion
is coordinated identically by residues Glu-19, His-70,how Glu-134 could participate in drug binding, consider-
ing that it is completely buried within the hydrophobic and their dyadic mates. As no metal salts were added
to the crystallization solution, the metal ion appears tocore of the protein.
be carried from the cell through protein purification and
crystallization, and its identity is unknown.BRC±TPP Complex Structure Determination
To determine the detailed architecture of the multidrug-
binding site of BRC and to gain insight into the mecha-
nism of drug binding, we crystallized BRC complexed TPP-Binding Pocket
The TPP-binding pocket is created by residues that orig-to one of the BmrR inducers and BRC ligands, tetraphen-
ylphosphonium (TPP). The structure of the BRC±TPP inate from helix a1 (Ile-23 and Val-28) and strands b3
(Tyr-51 and Ala-53), b4 (Tyr-68 and Ile-71), and b7 (Ile-complex was solved with the molecular replacement
program EPMR (C. R. Kissinger, unpublished data) using 136). The TPP molecule wedges into the binding cavity
using one of its four phenyl rings as a lead prong (Figurethe apo BRC structure as a search model. There is one
monomer in the asymmetric unit. The current model of 4). Each of the four rings of the TPP molecule contributes
to binding and makes van der Waals contacts to thethe BRC±TPP complex to 2.8 AÊ resolution has an R
factor of 23.5% and includes 130 residues, 11 water side chains of the above five hydrophobic residues while
one phenyl ring stacks against the aromatic side chainmolecules, one TPP molecule, one divalent metal ion,
and one sulfate ion (Table 1). Residues 1, 34±49, 78±80, of residue Tyr-51 and another phenyl ring stacks against
the aromatic side chain of residue Tyr-68. As anticipatedand 141±148 are disordered and are not included in the
final BRC model. from the structure of the apo protein and mutational
studies, the key electrostatic component of TPP binding
is residue Glu-134, which is located at the bottom ofOverall Structure of the BRC±TPP Complex
The global structures of the TPP-bound BRC monomer the binding pocket. The negatively charged carboxylate
group of Glu-134 makes an electrostatic contact with theand dimer are very similar to those of the apo protein
(Figure 3). An overlay of the Ca atoms of residues 2±27, positively charged TPP molecule. In the TPP molecule,
the formal positive charge is carried by the phosphorus50±76, 81±140, and 149±158 of the apo and drug-bound
monomers results in a root-mean-square difference atom of TPP, which is 7.8 AÊ away from the carboxylate
oxygen OE2. However, since TPP is a conjugated mole-(rmsd) of 0.81 AÊ . There are no gross differences in the
dimerization interface of BRC in response to TPP bind- cule, its phenyl rings can carry a partial positive charge.
The distance between the carboxylate oxygen OE2 anding, and the rmsd for the apo and drug-bound dimers is
0.83 AÊ after superimposition of the Ca atoms of residues the closest atom of TPP is 3.2 AÊ , and the low dielectric
constant (z2) of the protein interior would strongly favor2±27, 50±76, 81±140, and 149±158 from both subunits.
Structural Basis of Multidrug Recognition by BmrR
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Figure 3. Structural Changes in BRC upon
TPP Binding
Apo BRC dimer (top) and TPP-bound BRC
(bottom) are represented as cyan ribbons.
Upon drug binding, residues 28±50 (shown
in red) undergo significant conformational
changes. A dotted line depicts disordered
residues 34±49. The metal-chelating residues
Glu-19, His-70, Glu-199, and His-709 are
shown as cyan balls and sticks, and binding-
pocket residues Glu-134 and Glu-1349 are de-
picted as blue balls and sticks. The bound
TPP molecules are shown as purple balls and
sticks, and the metal ion is shown as a red
sphere. This figure was generated with Sybyl
(Tripos).
this electrostatic interaction. As seen from the distribu- molecule, Wat1, occupies the void created by the dis-
placed Tyr-33 side chain and forms a hydrogen bondtion of the electrostatic surface potential, Glu-134 cre-
ates the negative charge inside the binding pocket (Fig- to Glu-134 (Figure 4).
The most important structural change in the BRC±ure 5, right) necessary to attract and bind a positively
charged drug, which is consistent with the inability of drug complex involves helix a2 (residues 34±42), which
is now disordered. The disordering extends to residuethe Glu-134 mutants to bind rhodamine. Finally, to com-
plement its electrostatic potential, the carboxylate oxy- 49, including the flexible-loop residues 43±48, which are
already disordered in apo BRC. Increased flexibility orgens of Glu-134 maintain their hydrogen bonds to
nearby residues Tyr-110 and Tyr-68. disordering of helix a2 was suggested from protease
cleavage studies (data not shown) which demonstrated
that rhodamine or TPP binding dramatically increaseConformational Changes
TPP binding induces dramatic local conformational trypsin cleavage between residues Lys-37 and Lys-38.
The observed unfolding of helix a2 is critical for drugchanges in the BRC protein, which make the binding
pocket accessible to the drug. These changes involve binding. In the absence of drugs, helix a2 lies across
the drug-binding pocket and completely blocks accesshelices a1 and a2 and the turn connecting them (Figure
3, bottom). In contrast to the apo structure, helix a1 is to the binding site (Figure 3, top; Figure 5, left). Further-
more, helix a2 stabilizes the apo conformation by in-rotated z108 around its amino terminus, and its carboxyl
terminus (residue Asn-30) is unwound. The tight turn serting residues Tyr-33 and Leu-36 into the core of the
protein with the former residue hydrogen bonding toconnecting helices a1 and a2, residues Ala-31±Ser-32±
Tyr-33, unfolds and extends into the solvent such that Glu-134 (Figure 2) and the latter making van der Waals
contacts to core residues Val-28 and Ile-23. To bindthe Ca atom of Tyr-33 is translated 11.5 AÊ from its apo
position and its side chain is completely removed from TPP, helix a2 must relocate, which, in turn, requires the
helix to unfold because of the stereochemical con-the protein core. The repositioning of residue Tyr-33 is
especially important because in the apo structure, Tyr- straints of the BRC structure (i.e., a folded nine-residue
a helix would be too short to connect residue Ser-34 to33 contributes one of the internal hydrogen bonds to
the buried carboxylate of Glu-134 (Figure 2), a bond residue Ser-42 [Figure 3, bottom]). These drug-depen-
dent conformational changes lead to the exposure of thethat is broken when drug binding takes place. A water
Cell
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Figure 4. The Fo-Fc Omit Map of the Tetraphen-
ylphosphonium Molecule Contoured at 2.5 s
BRC residues making contact to the TPP and
water molecule Wat1 are shown in cyan. The
TPP molecule is shown in red. Dashed lines
indicate hydrogen bonds and contacts be-
tween selected atoms with distances given
in AÊ . This figure was generated with O (Jones
et al., 1991).
internal drug-binding pocket where the phenyl moieties As intimated above, this nine-residue a helix is likely to
possess an intrinsic flexibility and to fluctuate betweenand charge of TPP sterically and functionally replace
the side chains of Tyr-33 and Leu-36 and thereby stabi- a folded and partially unfolded conformation, thus
allowing drugs to enter the internal binding site. Indeed,lize the drug-bound conformation.
The ligand-induced helix-to-coil transition undergone the average thermal parameter of the Ca atoms of helix
a2 is 52 AÊ 2, which is significantly higher than the averageby BRC is uncommon and contrasts with the reverse
process that is observed in several DNA-binding pro- thermal parameter (32 AÊ 2) of the Ca atoms of the remain-
der of the protein. Similar flexibility, and its implied im-teins and the activation domains of certain transcription
factors upon ligand binding (O'Neil et al., 1991; Ferre- portance in ligand binding, has been observed for sev-
eral members of the lipocalin family (Chen et al., 1998;D'Amare et al., 1994; Spolar and Record, 1994; Nagadoi
et al., 1995; Schumacher et al., 1995; Kussie et al., 1996; Constantine et al., 1998). Finally, the aromatic cationic
drugs themselves might actively destabilize helix a2 bySpronk et al., 1996; Uesugi et al., 1997). However, the
DNA-binding proteins, restriction enzyme BamHI (New- repelling the positively charged lysines Lys-35, Lys-37,
and Lys-38 located on the outer face of this helix.man et al., 1995) and transcription factor Ets-1 (Petersen
et al., 1995; Donaldson et al., 1996), show similar helical
unfolding. When BamHI binds its specific DNA site, the Model of the BRC±Rhodamine Complex
Our attempts to obtain data-quality crystals of BRCC-terminal helix unfolds into an extended arm that
makes additional contacts to its DNA ligand. More anal- complexed to other drugs, rhodamine in particular, have
been unsuccessful. However, using the TPP±BRC struc-ogous to BRC, specific DNA binding by Ets-1 induces
unfolding of an a helix in the DNA-binding inhibitory ture as a template, a rhodamine±BRC complex was
modeled by manually docking rhodamine in the bindingregion of the protein. This helix blocks access of the
recognition helix to its cognate DNA site and must unfold pocket. Subsequently, the DOCK option in the software
package Sybyl (Tripos) was used to minimize the badto allow high-affinity binding.
contacts between the two molecules by allowing the
position of the rhodamine molecule to change while theMechanism of Ligand Entry
The structures of apo and TPP-bound BRC capture the protein structure was held fixed. From this BRC±drug
complex model (Figure 6), it is clear that rhodamine is notend states of the drug-binding event. A key question is
how does TPP gain entrance to the internal binding only able to make van der Waals and stacking contacts
similar to those observed in the TPP±BRC complex,site of BRC (BmrR). The electrostatic surface potential
surrounding the binding site (Figure 5, left) suggests a but can also penetrate deeper into the core of BRC.
Specifically, the positively charged nitrogen of the aminopathway that involves residue Glu-21. This residue is
proximal to helix a2 and creates a negative patch on ethyl group of rhodamine can be positioned as close as
2.9 AÊ from the oxygen of the carboxylate group of Glu-the protein that could initially attract and possibly bind
TPP and other cationic ligands of BRC. From here, the 134, in contrast to the 7.8 AÊ distance for the positively
charged phosphorus of TPP, without steric clash. Thepositively charged molecules could slide toward the
drug-binding pocket. However, drug binding cannot oc- closer approach of the positive charge on rhodamine to
the carboxylate of Glu-134 likely accounts for most ofcur unless helix a2 unfolds and moves out of the way.
Structural Basis of Multidrug Recognition by BmrR
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Figure 5. The Electrostatic Surface Potential of the Monomeric Apo BRC (Left) and TPP-Bound BRC (Right)
Regions of the negative potential are colored red; positive, blue; and neutral, white. In apo BRC (left), residues 29±42 are shown as sticks
where carbons are white; nitrogens, blue; and oxygens, red. These residues are excluded from the surface calculations. In the TPP-bound
BRC (right), a molecule of TPP is shown as a stick representation where the phosphorus is yellow and carbons are white. The TPP molecule
is excluded from the surface calculations. This figure was generated with GRASP (Honig and Nicholls, 1995).
its z100-fold higher binding affinity in comparison with thus initiates transcription (Summers, 1992; Ansari et
al., 1995; Hidalgo et al., 1997). The structures of theTPP. The modeled rhodamine±BRC structure, together
with TPP±BRC complex, emphasizes the critical role apo BRC and the TPP-bound protein reveal no large
conformational or structural changes outside of theof the steric complementarity in discrimination against
other, less planar or more branched hydrophobic cat- drug-binding region (Figure 3). Therefore, it can be hy-
pothesized that the unwinding and relocation of helixions. Nevertheless, the precise description of the rhoda-
mine±BRC and other drug±BRC complexes awaits the a2 serves as an inducing signal between the drug-bind-
ing and the DNA-binding domains of BmrR. For example,determination of their crystal structures.
the DNA-untwisting activity of the N-terminal domain
of BmrR can be repressed by its intra- or intersubunitTranscription Activation
Binding of drugs to the BRC domain converts BmrR into contacts with helix a2. Through the disordering of helix
a2, drug binding would impair such an interaction andan activator of transcription from the bmr promoter. This
activation, similar to other MerR-type proteins (Sum- relieve repression. The 30-residue linker, connecting the
DNA-binding and the drug-binding domains is more thanmers, 1992; Holmes et al., 1993; Ansari et al., 1995;
Gaudu and Weiss, 1996; Hidalgo et al., 1997), is likely sufficient to allow this possibility. Clearly, the determina-
tion of the molecular mechanism by which drug bindingto occur through untwisting of the spacer region of the
promoter, which serves as the BmrR-binding site (Ahmed turns BmrR into a transcription activator entails further
biochemical investigation and, ultimately, the structureet al., 1994). This untwisting leads to the proper position-
ing of the promoter motifs binding RNA polymerase and of a BmrR-promoter-drug ternary complex.
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Figure 6. Structure-Based Model of Rhoda-
mine Bound to BRC
Rhodamine is displayed as purple balls and
sticks and the protein atoms as cyan balls
and sticks. Dashed lines indicate potential
interactions between selected atoms with
distances given in AÊ . This figure was gener-
ated with O (Jones et al., 1991).
50 kV and 100 mA. The data were processed using BIOTEX (Molecu-In summary, the X-ray structures of apo BRC and the
lar Structure Corporation, Inc., Woodlands, TX).TPP±BRC complex reveal the helix-to-coil transition of
helix a2 that is required for high-affinity drug binding.
Structure Determination of Apo BRCMoreover, the structures identify residue Glu-134, which
The structure of apo BRC was solved by multiple isomorphous
is completely solvent inaccessible in the apo structure, replacement (MIR) (Blundell and Johnson, 1976; Drenth, 1994).
as the key to cation selectivity, while a number of nonpo- Heavy atom derivatives were prepared by soaking native crystals in
lar and aromatic side chains impose specific require- solutions of KAuCl4 or HgCl2, and the selenomethionine-substituted
protein (LeMaster and Richards, 1985) was also a useful derivativements on drug size and shape. The interactions between
(Table 1). Relevant intensity data collection statistics are listed inBRC and tetraphenylphosphonium suggest a similar
Table 1. Initially, one heavy atom site was identified in the differencebinding mode for other hydrophobic cationic ligands of
Patterson map of the gold derivative. Difference and cross-differ-
BmrR. It is tempting to speculate that other multidrug- ence Fourier analyses allowed the identification of the second gold
binding proteins, including multidrug transporters, uti- site, one mercury site, and one selenium site. The heavy atom pa-
lize some of these stereochemical and structural princi- rameters were refined via maximum likelihood to 3.0 AÊ resolution
using the software package PHASES-95 (Furey and Swaminathan,ples, such as relocation or disordering of secondary
1997). At this stage, we were able to resolve the space group ambi-structure elements to expose otherwise inaccessible
guity between the enantiomorphs P41212 and P43212 in favor of thekey residues, to bind their structurally dissimilar ligands
former. The overall figure of merit was 0.45 in the P41212 spaceand substrates. group, while in the P43212 space group it was only 0.35. The initial
MIR map was uninterpretable, and solvent flattening (70% estimated
solvent) as implemented in PHASES-95 was used. The solvent-flat-Experimental Procedures
tened map was readily interpretable and had the correct handed-
ness as revealed by the presence of a good electron density for aCrystallization
right-handed helix. Besides this a helix, seven b strands were alsoCrystals of the 158-residue drug-free BRC (apo BRC), which take
obvious, and a polyalanine trace was fit to the density. Iterativethe tetragonal space group P41212 with unit cell dimensions: a 5
cycles of model building in O (Jones et al., 1991) and phase combina-b 5 76.3 AÊ , c 5 96.0 AÊ , a 5 b 5 g 5 908, crystallized out of solutions
tion, as implemented in PHASES-95, resulted in the addition of twocontaining 4.3 M NaCl, 20 mM Tris´HCl (pH 8.5), and 2 mM MnCl2, as
more a helices and one b strand. This model included residuesdescribed previously (Zheleznova et al., 1997). Crystals of BRC±TPP
1±42, 48±76, 81±141, and 148±158. The initial R factor of the modelcomplex were grown from solutions containing 10 mM TPP, 1.5 M
was 42.6%.(NH4)2SO4, 0.1 M sodium cacodylate (pH 6.5), and 5% 2-methyl-2,
4-pentanediol. These crystals assume the hexagonal space group
P6222 with unit cell dimensions: a 5 b 5 82.6 AÊ , c 5 104.5 AÊ , a 5 Structure Determination of the BRC±TPP Complex
b 5 908, g 5 1208. The structure of the BRC±TPP complex was solved by molecular
replacement with the program EPMR, which finds crystallographic
molecular replacement solutions using an evolutionary search algo-X-Ray Data Collection and Processing
X-ray intensity data for apo BRC were collected to 2.7 AÊ resolution rithm (C. R. Kissinger and D. K. Gehlhaar, unpublished data). The
program optimizes the three rotational and three positional parame-at room temperature with an Area Detector Systems Corporation
(ADSC) multiwire area detector (Xuong et al., 1985) using a Rigaku ters for the search model with respect to a calculated correlation
coefficient between Fo and Fc. At the end of this evolutionary optimi-RU200-H rotating anode X-ray generator with a graphite monochro-
mator (40 kV, 150 mA). The data were processed with software zation, a rigid-body refinement of the orientation and position of the
search model is performed. We used data in the resolution rangeprovided by ADSC. X-ray intensity data for the BRC±TPP complex
were collected to 2.8 AÊ resolution at room temperature on an R-AXIS 15.0 AÊ to 4.0 AÊ and the entire apo BRC monomer as a search model.
Both P6222 and enantiomorph P6422 were tested, but only P6222IV imaging plate system using a RIGAKU RU300 rotating anode X-ray
generator equipped with double focusing mirrors and operating at yielded a correct solution. P6422 did not yield a solution. The correct
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solution had a correlation coefficient of 65.1% and an R factor of protein model contains residues 2±33, 50±77, 81±140, and 149±158.
Residues Tyr-33, Thr-75, Ser-82, and Ser-83 were refined as alanines37.4% (Table 1).
because the density for their side chains is completely missing. The
stereochemical quality of the structure is very good (Laskowski etModel Refinement: Apo BRC and BRC±TPP Complex
al., 1993) (Table 1), but there are two residues Ser-62 and Ser-83 thatPrior to refinement, 10% of all the data were set aside for cross-
are outliers on the Ramachandran plot. Residue Ser-83 is located invalidation purposes. The initial apo BRC model underwent positional
a flexible loop that neighbors a disordered region, and residue Ser-least-squares refinement using data in the resolution range 20.0 AÊ
62 is located in a turn region; their electron densities are definableto 3.0 AÊ , as implemented in software package TNT (Tronrud et al.,
but poor. Relevant crystallographic statistics is listed in Table 1.1987; Tronrud, 1997). After convergence, the R factor was 27.8%.
The resolution was extended to 2.7 AÊ , and positional and tightly
Mutagenesisrestrained thermal-parameter refinement was carried out. Interven-
Each mutant variant of BRC was obtained by cloning an appropri-ing model rebuilding was done using O. At this stage, solvent mole-
ately mutagenized PCR product encompassing the BRC-encodingcules were positioned into overlapping 2Fo-Fc (.1 s) and Fo-Fc (.3
region into the pHPThioFus expression vector, followed by proteins) densities that were located within 3.4 AÊ distance from a hydrogen
expression and purification as described for the wild-type BRCdonor or acceptor. Their presence was additionally verified with
(Markham et al., 1996). Mutagenized PCR products were obtainedomit maps in which these molecules were removed, the model re-
by crossover PCR with two standard primers defining the ends offined, and Fo-Fc omit electron density maps calculated and in-
the PCR product and two complementary mutagenic primers. Eachspected. Only solvent molecules with B factor less than 80 were
mutant construct was resequenced to verify the correctness of theincluded in the final model. In the apo structure, the subunit-teth-
substitution and the absence of spontaneous PCR-generated muta-ering metal ion was refined as Mn21 at the occupancy of 0.5 because
tions.of its location on a crystallographic two-fold axis (Tronrud, 1997).
The final model was verified by a series of Fo-Fc omit electron density
maps in which 10% of the model was omitted and the remaining Acknowledgments
structure refined until convergence (typically 50 cycles). This ap-
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chemistry with no outliers. Residue Arg-1 was refined as an alanine
because the density for its side chain is missing. Relevant crystallo- References
graphic statistics are listed in Table 1.
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